Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Product royalties	$ 924,272		$ 1,779,373
Research revenues				13,375
Contract revenues	2,072,590	1,875,446	5,603,516	34,677,583
Total Revenues:	2,996,862	1,875,446	7,382,889	34,690,958
Cost of product royalties	643,486	375,000	1,708,693	1,125,000
Expenses:
Research and development	16,387,194	12,546,912	41,177,577	23,804,276
General and administrative	3,039,255	2,992,354	9,060,265	8,042,433
Related party general and administrative, net	9,750	20,000	39,250	65,750
Total Expenses:	19,436,199	15,559,266	50,277,092	31,912,459
(Loss) income from operations	(17,082,823)	(14,058,820)	(44,602,896)	1,653,499
Interest (expense) income, net	(450,328)	90,167	(281,812)	210,284
Derivative (loss) gain	(917,863)	(3,525,011)	499,671	(8,871,050)
Other (expense) income, net	(35,433)	16,377	(154,061)	63,237
Loss before taxes	(18,486,447)	(17,477,287)	(44,539,098)	(6,944,030)
Income tax expense			(85,000)
Net loss attributable to common stockholders	$ (18,486,447)	$ (17,477,287)	$ (44,624,098)	$ (6,944,030)
Basic and diluted earnings per share	$ (0.49)	$ (0.58)	$ (1.18)	$ (0.23)
Weighted average common stock shares outstanding	38,076,606	30,071,813	37,864,248	29,768,620